The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
NCT ID: NCT05617352
Last Updated: 2022-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1659 participants
OBSERVATIONAL
2022-05-01
2022-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY
NCT05570487
Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
NCT05604664
Improve the Treatment of Thoracic Esophageal Cancer
NCT01137123
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
NCT05420480
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
NCT06241066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2F Group
Patients with Two-field Lymphadenectomy
Since the data were collected retrospectively, there were no interventions
Since the data were collected retrospectively, there were no interventions
3F Group
Patients with Three-field Lymphadenectomy
Since the data were collected retrospectively, there were no interventions
Since the data were collected retrospectively, there were no interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Since the data were collected retrospectively, there were no interventions
Since the data were collected retrospectively, there were no interventions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Histologically confirmed primary thoracic esophageal squamous cell carcinoma,
* 3\. Staging PT1b-4A, N0-3, M0 AJCC eighth edition
* 4\. Excluding lymph node dissection \< 15, (meeting the guideline criteria)
* 5\. The tumor located in the lower middle thoracic.
Exclusion Criteria
* 2\. Patients with distant metastasis confirmed by imaging
* 3\. Patients with obvious surgical contraindications.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yongtao Han
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongtao Han
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCCH-TS2204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.